Gang Yuan Qiuli Liu Dali Tong Gaolei Liu Yuting Yi Jun Zhang Yao Zhang Lin-Ang Wang Luofu Wang Rongrong Chen Yanfang Guan Xin Yi Weihua Lan Jun Jiang
10.1080/15384047.2018.1470732
Cancer Biol Ther
2018;19(9):766-772.
vhl disease hemangioblastoma pheochromocytoma renal cell carcinoma sunitinib
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/29947576/
Antineoplastic Agents / therapeutic use Protein Kinase Inhibitors / therapeutic use Sunitinib / therapeutic use von Hippel-Lindau Disease / drug therapy
Antineoplastic Agents / therapeutic use Protein Kinase Inhibitors / therapeutic use Sunitinib / therapeutic use von Hippel-Lindau Disease / drug therapy Case Reports Adult Antineoplastic Agents / administration & dosage Antineoplastic Agents / adverse effects Carcinoma, Renal Cell / diagnosis Carcinoma, Renal Cell / drug therapy Carcinoma, Renal Cell / etiology Female Humans Magnetic Resonance Imaging Male Middle Aged Phenotype Protein Kinase Inhibitors / administration & dosage Protein Kinase Inhibitors / adverse effects Retrospective Studies Sunitinib / administration & dosage Sunitinib / adverse effects Tomography, X-Ray Computed Treatment Outcome von Hippel-Lindau Disease / diagnosis von Hippel-Lindau Disease / genetics Antineoplastic Agents Protein Kinase Inhibitors Sunitinib
PMC6154838
29947576
A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
2018